(Novo bag could do better, did buy low but damn could do better)
From obesity drugs to cardiology, a slew of drugs and therapies are coming up for approval in the year ahead
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
My Eli Lilly shares are at all-time highs again
(Novo bag could do better, did buy low but damn could do better)
From obesity drugs to cardiology, a slew of drugs and therapies are coming up for approval in the year ahead